Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | F2RL3 | Q96RI0 | 8/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3012843 | 0.91 | SMN1; SMN2 (0.37) | SMN1; SMN2MAPTRAB9ANPC1F2RL3 | |
| SCHEMBL3009905 | 0.90 | ALDH1A1 (0.38) | SMN1; SMN2F2RL3KDM4E | |
| SCHEMBL3006118 | 0.89 | RAB9A (0.40) | SMN1; SMN2MAPTRAB9ANPC1F2RL3 | |
| SCHEMBL3016776 | 0.88 | SMN1; SMN2 (0.39) | SMN1; SMN2MAPTRAB9ANPC1KDM4E | |
| SCHEMBL3006925 | 0.88 | RAB9A (0.38) | SMN1; SMN2MAPTRAB9ANPC1F2RL3 | |
| SCHEMBL3016255 | 0.88 | DNM1L (0.35) | SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL3016483 | 0.88 | SMN1; SMN2 (0.39) | SMN1; SMN2MAPTRAB9ANPC1CYP2C9 | |
| SCHEMBL3014450 | 0.87 | KDM4E (0.41) | SMN1; SMN2MAPTRAB9ANPC1F2RL3 | |
| SCHEMBL3015787 | 0.87 | MAPT (0.41) | SMN1; SMN2MAPTF2RL3RECQL | |
| SCHEMBL3000449 | 0.87 | RAB9A (0.39) | SMN1; SMN2MAPTRAB9ANPC1F2RL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722681-B2 | N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases | NV REMYND (BE) | 2014-05-13 | — | — | US | disclosed |
| US-20100197703-A1 | N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES | NV REMYND (BE) | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197703-A1 | N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES | SMN1; SMN2, HTT, SNCA | SMN1; SMN2 1/4885MAPT 18/4885RAB9A 2943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.